Results 31 to 40 of about 684,663 (243)
Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.
Histology and histopathology, 2021 Programmed death-ligand 1 (PD-L1) is an inhibitory transmembrane protein that can prevent autoimmune response. Upregulated PD-L1 serves as a predictive biomarker for patients who may respond well to immune checkpoint therapies. However, variable associations of PD-L1 level with prognoses have been reported.
Su, Bor Chyuan +6 more
openaire +3 more sources
PD-L1 sensitivity and specificity of antibody clone 29E.2A3 for PD-L1.
, 2021 A.Western blot of cell lysates from cultured human breast cancer cell lines known to express (MDA-MB-231) or not to express PD-L1 (MCF-7) using E1L3N Rabbit mAb, confirming the PD-L1 status of these two cell lines. B.
James M. Rae (7876037) +15 more
core +1 more source
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression [PDF]
, 2023 Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes with better ...
Raza, Afsheen +45 more
core +1 more source
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
JCI Insight, 2022 Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy and has been applied to clinical medicine.
Ray Sagawa +18 more
doaj +1 more source
Cell Communication and Signaling, 2023 Background PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response in a variety of solid tumors, including non-small cell lung cancer (NSCLC).
Anudari Letian +5 more
doaj +1 more source
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression [PDF]
Journal of Clinical Investigation, 2018 Programmed death-ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher expression of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1-negative patients also respond to ...
Haidong Tang +20 more
openaire +2 more sources
The function and regulation of PD-L1 in immunotherapy
ADMET and DMPK, 2017 PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors.
Libin Guo, Yao Lin, Hang Fai Kwok
doaj +1 more source
Molecular Oncology, 2023 Alternative sources of tumour information need to be explored in patients with non‐small cell lung cancer (NSCLC). Here, we compared programmed cell death ligand 1 (PD‐L1) expression on cytology imprints and circulating tumour cells (CTCs) with PD‐L1 ...
Mustafa Abdo +16 more
doaj +1 more source
Basis of PD1/PD-L1 Therapies [PDF]
Journal of Clinical Medicine, 2019 It is obvious that tumor cells have developed a number of strategies to escape immune surveillance including an altered expression of various immune checkpoints, such as the programmed death-1 receptor (PD-1) and its ligands PD-L1 and PD-L2. The interaction between PD-1 and PD-L1 results in an activation of self-tolerance pathways in both immune cells ...
openaire +2 more sources
Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies [PDF]
Cancer Research, 2015 Abstract Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive antitumor activity. Patients with tumors expressing PD-L1 are most likely to respond to this treatment. The aim of our study was to develop a noninvasive imaging technique to determine tumor PD-L1 expression in vivo ...
Heskamp, S. +7 more
openaire +3 more sources